Navigation Links
Nile Therapeutics Announces Information in Compliance With NASDAQ Marketplace Rule 4350 and Reiterates 2009 Objectives
Date:3/18/2009

SAN FRANCISCO, March 18 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a leading company in the development of novel therapeutics for heart failure patients, today announced that, pursuant to Nasdaq Marketplace Rule 4350(b)(1)(B), its audited financial statements for the fiscal year ended December 31, 2008, included in the Company's Annual Report on Form 10-K, filed on March 12, 2009, contained a going concern qualification from its independent registered public accounting firm, Hays & Company LLP.

This announcement is required by Nasdaq Marketplace Rule 4350(b)(1)(B), which requires separate disclosure of receipt of an audit opinion containing a going concern qualification. This announcement does not represent any change or amendment to the company's financial statements or to its Annual Report on Form 10-K for the fiscal year ended December 31, 2008.

2009 Objectives

Nile is focused on very specific clinical and corporate objectives:

  • To complete the dosing of a 30 patient, placebo-controlled Phase 2b study in the 3rd quarter of 2009. This study is designed to provide additional clinical evidence that CD-NP enhances renal function. This finding would favorably differentiate CD-NP from other acute heart failure therapies.
  • Through financing, partnering or other strategic alternative, secure the resources necessary to continue development activities beyond the 30 patient Phase 2b study.
  • To start enrollment into the 330 patient double-blind, placebo-controlled Phase 2b acute heart failure Proof of Concept study.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medarex to Present at the Needham Cancer Therapeutics Conference
2. Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
3. FDA Accepts IND for Arno Therapeutics Pan-DAC / Akt Inhibitor, AR-42
4. Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA
5. United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso)
6. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
7. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
8. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
9. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... This report analyzes the worldwide markets for Bioinformatics in US$ ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... estimates and forecasts are provided for the period 2013 through ... markets. Market data and analytics are derived from primary and ...
(Date:9/16/2014)... --The emerging field of molecular electronics could take ... enabling the construction of tiny circuits from molecular ... would take on the roles currently played by ... of researchers from five Japanese and Taiwanese universities ... small-scale electronics: a molecule called picene. In a ...
(Date:9/16/2014)... BlueInGreen® , a water quality company ... dissolved gases into liquids, announced the addition of ... representative firm to its sales network. H2Flow will ... and wastewater applications in the Canadian provinces of ... 1992 and serves Quebec and Ontario markets for ...
(Date:9/16/2014)... CIRTEC Medical Systems’ Board of Directors has ... CIRTEC. , “I am delighted to be joining ... Brian Highley. “The company has made great strides improving ... over the past two years. The goal now is ... expand the services Cirtec offers its medical device customers.” ...
Breaking Biology Technology:Global Bioinformatics Industry 2Global Bioinformatics Industry 3Global Bioinformatics Industry 4Global Bioinformatics Industry 5Global Bioinformatics Industry 6Global Bioinformatics Industry 7Global Bioinformatics Industry 8Global Bioinformatics Industry 9Global Bioinformatics Industry 10Global Bioinformatics Industry 11Global Bioinformatics Industry 12Global Bioinformatics Industry 13Global Bioinformatics Industry 14Global Bioinformatics Industry 15Global Bioinformatics Industry 16Global Bioinformatics Industry 17Global Bioinformatics Industry 18Global Bioinformatics Industry 19Global Bioinformatics Industry 20Global Bioinformatics Industry 21Global Bioinformatics Industry 22Global Bioinformatics Industry 23The future face of molecular electronics 2BlueInGreen® Expands into Canada – Signs Representative Agreement with H2Flow Equipment Inc. 2
... To highlight its 20 years of experience as ... ( www.microtestlabs.com ) is offering free microbial identification ... tests, to eligible attendees visiting the Microtest exhibit, #828, ... highlight Microtest,s wide range of laboratory testing and validation ...
... RGEN ) announced today that the Company ... will present at the BIO CEO and Investor Conference ... at the Waldorf-Astoria Hotel, 301 Park Avenue, New York, ... available via Repligen,s website at www.repligen.com and ...
... Secretropin(R) , the first clinically proven natural stimulator of ... as a more desirable "first step" approach to pursuing ... Secretropin(R) is only available through ... to increase the body,s own production and release of ...
Cached Biology Technology:Microtest Labs Offers Free Microbial Identification Testing, Free Shipping on Other Tests, to MD&M West Attendees 2Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST 2Secretropin(R) - Effective, Preferable, Affordable as an Alternative to Injectable Growth Hormone - Gains Momentum 2
(Date:9/16/2014)... "molecular brakes" that time the generation of important cells ... cells" translate sound waves into electrical signals that are ... If the arrangement of the cells is disordered, hearing ... will be published in The Journal of Neuroscience ... Hey2 act as brakes to prevent hair cell generation ...
(Date:9/16/2014)... make us sick can take up residence in and ... or other troublesome symptom, according to new research at ... , On average, healthy individuals carry about five types ... in BioMed Central Biology . The study is ... viruses in healthy people. , The research was ...
(Date:9/16/2014)... chunk of rock hit the Yukatan peninsula near the site ... 100 teratons of TNT. It left a crater more than ... and volcanism are widely accepted to have wiped out the ... But what happened to the plants on which the dinosaurs ... University of Arizona reveals that the meteorite impact that spelled ...
Breaking Biology News(10 mins):Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Healthy humans make nice homes for viruses 2Healthy humans make nice homes for viruses 3Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3
... - Primary Energy Recycling Corporation (TSX: PRI), (the "Company") a clean energy company ... announced its financial and operational results for the first quarter ended March ... Highlights for the ... 4.3% for the three months ended March 31, 2010, ...
... Spain and the UK have identified the final piece in ... Published today by PNAS, the breakthrough discovery by the Consejo ... of East Anglia (UEA) has implications for agribusiness, the environment ... deposit which accumulates in the seeds, beans and tubers of ...
... cystic fibrosis can be caused by genetic "nonsense mutations" ... Bedwell, Ph.D., a professor in the University of Alabama ... now closer to producing drugs that will fix this ... Bedwell is a renowned researcher on the select group ...
Cached Biology News:Primary Energy Reports Improved First Quarter Results 2Primary Energy Reports Improved First Quarter Results 3Primary Energy Reports Improved First Quarter Results 4Primary Energy Reports Improved First Quarter Results 5Scientists discover final piece in phytate jigsaw 2Drug may treat cystic fibrosis, other diseases caused by 'nonsense mutations,' UAB researcher says 2